Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are generic/terminology-focused and are not addressed by the provided prescribing information; however, the key pharmacologic mechanism (P2Y12 inhibitor) is supported. Other claims about marketing/brand availability and search behavior are not supported or contradicted by the label excerpts provided.
Category Scores
Accurate Statements
Cangrelor is a P2Y12 inhibitor.
Label 12.1: “Cangrelor is a direct P2Y12 platelet receptor inhibitor…”
Unsupported Statements
Cangrelor is the generic name for the investigational antiplatelet drug cangrelor.
The provided label excerpts do not address generic-name status or whether there is an “investigational antiplatelet drug” named cangrelor.
Cangrelor is not widely marketed under a different generic name.
The provided label excerpts do not discuss market availability or alternative generic naming.
There are no specific, established brand-name products tied to “cangrelor” provided.
The provided label excerpts identify a brand product name: KENGREAL (with active ingredient cangrelor). Therefore the specific statement is not supported by the provided excerpts.
Cangrelor is primarily discussed in the context of clinical development rather than routine commercial prescribing.
The provided label excerpts include an FDA indication, dosage/administration, contraindications, and warnings for KENGREAL, which is consistent with routine prescribing information.
Using the spelling “cangrelor” is the most direct match for searching in databases or trials.
The provided label excerpts do not address database/search guidance.
Contradictions
Low
AI Statement
There are no specific, established brand-name products tied to “cangrelor” provided.
Label Reference
Label header/excerpts: “KENGREAL is indicated…” and “Drug product: KENGREAL; Active ingredient: cangrelor.”
Important Omissions
No omission of label-relevant safety/efficacy/dosing content occurred because the AI claims were purely about terminology/branding/search behavior and did not request or imply dosing, contraindications, warnings, interactions, or patient population guidance.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are non-clinical/terminology-focused. The only clinically relevant mechanism claim (P2Y12 inhibition) is supported by the label. No dosing, contraindication, warning, monitoring, or drug-interaction instructions were provided that could directly affect patient safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided prescribing information and one contradicts the presence of a labeled brand name (KENGREAL) for cangrelor.
Suggested Improvement
Limit claims to label-supported facts (e.g., mechanism as a direct P2Y12 receptor inhibitor, and that the labeled product is KENGREAL containing cangrelor). Remove or qualify statements about market availability, branding completeness, clinical-development vs routine prescribing framing, and database-search guidance since these are not addressed in the provided label excerpts.